Table 2

Eradication rates of each therapy group

AnalysisVA-dualVAC-tripleDifference from VAC-triple
(adjusted 95% CI for difference)
P value for difference*P value for non-inferiority†
ITT84.5% (142/168)89.2% (149/167)4.7% (–11.8% to 2.4%)0.2030.073
 95% CI78.2% to 89.6%83.5% to 93.5%
PP87.1% (142/163)90.2% (148/164)3.1% (–9.9% to 3.7%)0.3720.024
 95% CI81.0% to 91.8%84.6% to 94.3%
  • *The p values were obtained from two-sided comparisons of difference between the VA-dual group and VAC-triple group.

  • †The p values were obtained from one-sided test comparisons of non-inferiority between the VA-dual group and VAC-triple group.

  • ITT, intention-to-treat; PP, per protocol; VAC-triple, vonoprazan, amoxicillin and clarithromycin triple therapy; VA-dual, vonoprazan and amoxicillin dual therapy.